We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+6.63%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$870M
AUM Growth
+$27M
Cap. Flow
+$16.7M
Cap. Flow %
1.92%
Top 10 Hldgs %
32.2%
Holding
103
New
12
Increased
47
Reduced
28
Closed
15

Top Buys

Rank Stock Value
1
IQV icon
IQVIA
IQV
+$16.5M
2
WGS icon
GeneDx Holdings
WGS
+$13.7M
3
DHR icon
Danaher
DHR
+$9.08M
4
DXCM icon
DexCom
DXCM
+$7.49M
5
ASND icon
Ascendis Pharma A/S
ASND
+$6.86M

Top Sells

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$27.6M
2
UNH icon
UnitedHealth
UNH
+$26.3M
3
SYK icon
Stryker
SYK
+$10.2M
4
GILD icon
Gilead Sciences
GILD
+$9.29M
5
PODD icon
Insulet
PODD
+$7.14M

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
26
DELISTED
Arcellx
ACLX
$11.5M 1.32%
174,276
+106,886
+159% +$6.65M
QDEL icon
27
QuidelOrtho
QDEL
$1.03B
$11.1M 1.28%
386,646
+202,968
+111% +$6M
OM icon
28
Outset Medical
OM
$79.9M
$10.5M 1.21%
549,052
+317,953
+138% +$4.96M
MBX
29
MBX Biosciences
MBX
$3.23B
$9.95M 1.14%
871,933
+543,610
+166% +$5.54M
XERS icon
30
Xeris Biopharma Holdings
XERS
$1.52B
$9.84M 1.13%
2,107,483
+327,029
+18% +$1.5M
NUVL
31
DELISTED
Nuvalent
NUVL
$9.13M 1.05%
119,623
+9,635
+9% +$705K
BCRX icon
32
BioCryst Pharmaceuticals
BCRX
$2.51B
$9.03M 1.04%
1,007,992
+7,430
+0.7% +$69.2K
PTCT icon
33
PTC Therapeutics
PTCT
$6.01B
$8.87M 1.02%
181,643
-98,671
-35% -$4.68M
MRUS
34
DELISTED
Merus
MRUS
$8.57M 0.99%
162,980
+134,750
+477% +$6.33M
EWTX icon
35
Edgewise Therapeutics
EWTX
$4.69B
$8.49M 0.98%
647,331
+221,924
+52% +$3.2M
ANIP icon
36
ANI Pharmaceuticals
ANIP
$1.72B
$8.38M 0.96%
128,478
+23,478
+22% +$1.53M
REPL icon
37
Replimune Group
REPL
$1.42B
$8.33M 0.96%
896,710
-53,689
-6% -$468K
RXST icon
38
RxSight
RXST
$292M
$8.24M 0.95%
633,874
+2,636
+0.4% +$39.6K
SNDX icon
39
Syndax Pharmaceuticals
SNDX
$1.7B
$8.13M 0.93%
867,813
+272,826
+46% +$3M
LIVN icon
40
LivaNova
LIVN
$4.53B
$7.88M 0.91%
175,000
+8,129
+5% +$335K
UPB
41
Upstream Bio Inc
UPB
$378M
$7.86M 0.9%
715,504
+481,941
+206% +$4.45M
KALV
42
DELISTED
KalVista Pharmaceuticals
KALV
$7.68M 0.88%
679,063
-74,689
-10% -$913K
DOCS icon
43
Doximity
DOCS
$4.74B
$7.41M 0.85%
120,834
+27,334
+29% +$1.53M
DGX icon
44
Quest Diagnostics
DGX
$26.1B
$7.36M 0.85%
40,997
-21,596
-35% -$3.75M
AXGN icon
45
Axogen
AXGN
$2.58B
$7.32M 0.84%
674,551
+137,719
+26% +$1.8M
ASND icon
46
Ascendis Pharma A/S
ASND
$16.2B
$7.27M 0.84%
+42,108
New +$6.86M
ATEC icon
47
Alphatec Holdings
ATEC
$1.51B
$7.2M 0.83%
648,871
+202,765
+45% +$2.33M
CSTL icon
48
Castle Biosciences
CSTL
$933M
$7.19M 0.83%
352,262
+1,711
+0.5% +$31.7K
MNKD icon
49
MannKind Corp
MNKD
$1.2B
$7.11M 0.82%
1,900,918
-592,918
-24% -$2.61M
OPRX icon
50
OptimizeRx
OPRX
$165M
$6.85M 0.79%
507,423
+32,423
+7% +$355K
1
2
3 4 5

Similar funds

MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
TC
TwinBeech Capital Purchase, New York $965M AUM 0.23% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM

Parkman Healthcare Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Parkman Healthcare Partners held 103 positions worth $870M, up 3.2% from $843M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Parkman Healthcare Partners's Q2 2025 filing shows 12 new, 47 increased, 28 reduced and 15 closed positions. Its largest new stake was IQVIA: 109,500 shares worth $17.3M. The largest sale was Becton Dickinson, an estimated $27.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Parkman Healthcare Partners's largest Q2 2025 buy was IQVIA: 109,500 shares worth $17.3M.
  • Parkman Healthcare Partners added most to Danaher in Q2 2025, an estimated $9.08M increase.
  • Parkman Healthcare Partners's biggest Q2 2025 reduction was Stryker, cutting an estimated $10.2M.
  • Parkman Healthcare Partners fully exited Becton Dickinson in Q2 2025, selling an estimated $27.6M.
  • Parkman Healthcare Partners's ten largest holdings make up 32% of its $870M portfolio in Q2 2025.
  • Parkman Healthcare Partners opened 12 new positions and closed 15 in Q2 2025.
  • Parkman Healthcare Partners's portfolio value rose 3.2% quarter-over-quarter to $870M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2025, filed 14 Aug 2025.